GTBP Stock Analysis: Buy, Sell, or Hold?
GTBP - GT Biopharma Inc. Common Stock
$0.36
-0.03 (-6.71%)
▼
5d:
-21.37%
30d:
-16.85%
90d:
-7.02%
WAIT
LOW Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 13, 2026
29d
Get Alerted When GTBP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: GTBP is down 21.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: GTBP is down 21.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: GTBP is currently trading at $0.36, which is considered oversold relative to its 30-day fair value range of $0.41 to $0.48.
Technical Outlook: Technically, GTBP is in a downtrend. The price is currently testing key support at $0.37. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $3.00 (+673.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GTBP is in a downtrend. The price is currently testing key support at $0.37. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $3.00 (+673.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.41 -
$0.48
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.7%)
- BULLISH: Trading 673.8% below Wall St target ($3.00)
- WARNING: Recommendation downgraded due to -21.4% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.41 -
$0.48
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.37
Resistance Level
$0.50
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.44
Wall Street Target
$3.00
(+673.8%)
Share & Embed Analysis
Last updated: July 14, 2026 2:49 PM ET
Data refreshes hourly during market hours. Next update: 3:49 PM
Data refreshes hourly during market hours. Next update: 3:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GTBP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$413 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$822 | 64 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 52 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
